By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
Are multiverses real? An astrophysicist explains why it depends on how you define ‘real’ - 24 astronauts are en route home from ISS after medical issue forces early exit
- 3Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
- 4Vacuum Cleaners That Are Not difficult To Use For Home
- 5We tasted one of the 10,000 Hershey's Dubai chocolate bars being resold on eBay. Is it worth the hype?
- 5 Most Expected Film Delivery
- Instructions to Pick the Right Senior Protection Plan.
- Beneficial Growing Conditions in West Africa Weigh on Cocoa Prices
- 2024 Style: The It-Things You Want in Your Closet
- 7 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
- Holiday weather forecast: Where travelers can expect a wintry mix, flooding and record warmth across the U.S.
- FDA proposes use of sunscreen ingredient popular in other countries
- Moving Pool Highlights for 2024
- Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says
